Skip to main content

JP Allison

First name:
JP
Last name:
Allison
Wei, S. ., Duffy, C. ., & Allison, J. . (2018). Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-18-0367 (Original work published 2018)
Sharma, A. ., Subudhi, S. ., Blando, J. ., Scutti, J. ., Vence, L. ., Wargo, J. ., … Sharma, P. . (2018). Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-18-0762 (Original work published 2018)
Goswami, S. ., Apostolou, I. ., Zhang, J. ., Skepner, J. ., Anandhan, S. ., Zhang, X. ., … Sharma, P. . (2018). Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI99760 (Original work published 2018)
Ariyan, C. ., Brady, M. ., Siegelbaum, R. ., Hu, J. ., Bello, D. ., Rand, J. ., … Allison, J. . (2018). Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 6(2), 189-200. https://doi.org/10.1158/2326-6066.CIR-17-0356
Khouri, I. ., Curbelo, F. ., Turturro, F. ., Jabbour, E. ., Milton, D. ., RL, B. . , Jr, … Sharma, P. . (2018). Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(5), 1011-1018. https://doi.org/10.1158/1078-0432.CCR-17-2777 (Original work published 2018)
, Spencer, C. ., Nezi, L. ., Reuben, A. ., Andrews, M. ., Karpinets, T. ., … Wargo, J. . (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.), 359(6371), 97-103. https://doi.org/10.1126/science.aan4236 (Original work published 2018)
Mbofung, R. ., McKenzie, J. ., Malu, S. ., Zhang, M. ., Peng, W. ., Liu, C. ., … Hwu, P. . (2017). HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications, 8(1), 451. https://doi.org/10.1038/s41467-017-00449-z (Original work published 2017)
Reuben, A. ., Spencer, C. ., Prieto, P. ., , Reddy, S. ., Miller, J. ., … Wargo, J. . Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genomic Medicine, 2. https://doi.org/10.1038/s41525-017-0013-8 (Original work published 2017)
Wei, S. ., Levine, J. ., Cogdill, A. ., Zhao, Y. ., Anang, N. ., Andrews, M. ., … Allison, J. . (2017). Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 170(6), 1120-1133.e17. https://doi.org/10.1016/j.cell.2017.07.024 (Original work published 2017)
Reuben, A. ., Gittelman, R. ., Gao, J. ., Zhang, J. ., Yusko, E. ., Wu, C. ., … Zhang, J. . (2017). TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 7(10), 1088-1097. https://doi.org/10.1158/2159-8290.CD-17-0256